PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Follow-Up Questions
Who is the CEO of PepGen Inc?
Dr. James Mcarthur is the President of PepGen Inc, joining the firm since 2021.
What is the price performance of PEPG stock?
The current price of PEPG is $2.28, it has increased 11.46% in the last trading day.
What are the primary business themes or industries for PepGen Inc?
PepGen Inc belongs to Biotechnology industry and the sector is Health Care
What is PepGen Inc market cap?
PepGen Inc's current market cap is $74.9M
Is PepGen Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for PepGen Inc, including 5 strong buy, 4 buy, 1 hold, 1 sell, and 5 strong sell
